Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-modified Low-density Lipoprotein or Tumor Necrosis Factor Alpha
Authors
Affiliations
Background: Sildenafil, vardenafil, and tadalafil are phosphodiesterase type 5 inhibitors (PDE5-Is) usually used in the treatment of erectile dysfunction (ED). Previously, we have shown the presence of myeloperoxidase-modified low-density lipoprotein (Mox-LDL) in the penises of patients with ED, and we have shown the impact of Mox-LDL on cyclic monophosphate (cGMP) level. In vitro, Mox-LDL triggered the inflammatory response by increasing the release of both interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-alpha) by endothelial cells (ECs) and monocytes respectively.
Objective: To determine whether or not the three therapeutically PDE5-Is protect against the proinflammatory effects of Mox-LDL or TNF-alpha on ECs.
Design, Setting, And Participants: ECs (EA.hy926) were incubated in the presence of either TNF-alpha (100 pg/ml) or Mox-LDL (200 microg/ml) with each of the three PDE5-Is (1 microM, 5 microM, and 10 microM) respectively. IL-8 production was measured in the supernatant after 48 h of incubation.
Measurements: All experiments were repeated at least three times. Statistical analysis was performed with an ANOVA.
Results And Limitations: Two-way ANOVA analysis showed that TNF-alpha alone (p<0.001) or Mox-LDL alone (p<0.001) increased IL-8 production. Sildenafil, vardenafil, or tadalafil alone did not generate an increase of IL-8 production. Tadalafil in combination with Mox-LDL and TNF-alpha showed a decrease of IL-8 (p<0.05) compared with sildenafil and vardenafil.
Conclusions: Among the three available PDE5-Is, tadalafil showed an additional potentially anti-inflammatory effect on relaxation. Those data could be considered for the chronic use of PDE5-Is, but extrapolations of experimental evidence to the clinical setting should be made cautiously.
Bai Z, Li P, Gao X, Zu G, Jiang A, Wu K Transl Psychiatry. 2024; 14(1):494.
PMID: 39695100 PMC: 11655633. DOI: 10.1038/s41398-024-03202-5.
Tawfik A, Radwan M, Abdulmonem M, Abo-Elenen M, Elgamal S, Aboufarha M World J Urol. 2022; 40(10):2505-2511.
PMID: 35802142 PMC: 9512753. DOI: 10.1007/s00345-022-04074-4.
Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments.
Morris G, Puri B, Olive L, Carvalho A, Berk M, Walder K BMC Med. 2020; 18(1):305.
PMID: 33070778 PMC: 7570030. DOI: 10.1186/s12916-020-01749-w.
Urios A, Ordono F, Garcia-Garcia R, Mangas-Losada A, Leone P, Gallego J Sci Rep. 2019; 9(1):17119.
PMID: 31745217 PMC: 6863868. DOI: 10.1038/s41598-019-53136-y.
Taoka R, Kakehi Y Asian J Urol. 2017; 4(3):158-163.
PMID: 29264225 PMC: 5717984. DOI: 10.1016/j.ajur.2017.02.004.